Billy Evans, partner of disgraced Theranos founder Elizabeth Holmes, is launching a new blood-testing startup named Haemanthus, raising $3.5 million to develop innovative diagnostic technology. Unlike Theranos, which crumbled due to fraudulent claims, Haemanthus is focused on reliable disease detection from small blood, urine, and saliva samples. The startup, which has received its first patent for a diagnostic machine, initially targets pet health before branching out to human diagnostics. Evans aims to carve a distinct path away from the shadow of his partnerâs controversial past in the healthcare tech industry.
Haemanthus, incorporated in February 2024, focuses initially on animal tests for pet health care, intending to expand into human diagnostics in the future.
Despite Elizabeth Holmes' fraught legacy, Billy Evans insists that Haemanthus is not a repeat of Theranos, highlighting their unique approach to medical diagnostics.
Collection
[
|
...
]